Biomea Fusion (BMEA) Q2 Loss Drops 44%

Biomea Fusion (BMEA -1.86%), a biotechnology firm focused on developing covalent inhibitors for metabolic diseases, released its second quarter 2025 results on August 5, 2025. Net loss attributable to common stockholders was $20.7 million for the three months ended June 30, 2025, down from $37.3 million in the same period of 2024, beating consensus estimates of a $0.53 loss per share for Q2 2025 with an actual reported loss of $0.51 per share. No revenue was recorded, meeting expectations for a pre-commerci ...